$25.39
Value $806M
COLL and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$25.39
Value $806M
$392.43
Value $356B
Collegium Pharmaceutical (COLL) has a market value of $806M and UnitedHealth (UNH) $356B. Over the last year, with dividends, COLL moved -44.8% and UNH +25.2%. The P/E is 21.1 for COLL and 22.4 for UNH. Dividend yield: COLL none, UNH 2.31%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
COLL$806M
UNH$356B
UNH is 442 times COLL
Revenue, 12 months
COLL$815M
UNH$450B
UNH is 552 times COLL
Net income, 12 months
COLL$38M
UNH$15.9B
UNH is 416 times COLL
Operating margin
COLL15.2%
UNH5.3%
9.9 points apart
ROIC
COLL19.2%
UNH11.3%
7.9 points apart
P/E
COLL21.1
UNH22.4
UNH is 1.1 times COLL
Dividend yield
COLL0.0%
UNH2.3%
2.3 points apart
5-year return
COLL+27.8%
UNH-4.4%
32.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
COLL+27.8%
UNH-4.4%
| Period | COLLWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -44.8%Price -44.8% | +25.2%Price +21.9% |
| 3 years since November 17, 2023 | +1.0%+0.3% a yearPrice +1.0% | -22.1%-8.0% a yearPrice -26.8% |
| 5 years since November 16, 2021 | +27.8%+5.0% a yearPrice +27.8% | -4.4%-0.9% a yearPrice -12.7% |
| 10 years since November 17, 2016 | +54.6%+4.5% a yearPrice +54.6% | +207.3%+11.9% a yearPrice +160.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
COLLCollegium PharmaceuticalUNHUnitedHealth
| Price | $25.39 | $392.43 |
|---|---|---|
| Market value | $806M | $356B |
| Enterprise value (EV) | – | $402B |
| P/E | 21.1 | 22.4 |
| P/E, 5-year median | 19.6 | 25.0 |
| P/B | 2.7 | 3.4 |
| EV/EBIT | – | 16.8 |
| Free cash flow yield | 41.7% | 6.4% |
| Revenue, 12 months | $815M | $450B |
|---|---|---|
| Net income, 12 months | $38M | $15.9B |
| Free cash flow, 12 months | $336M | $22.8B |
| Earnings per share, 12 months | $1.20 | $17.52 |
| Revenue growth, year on year | 23.6% | 11.8% |
| Revenue growth a year, past | +20.3%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | +17.9%over 5 years | -3.8%over 5 years |
| Gross margin | 59.1% | 88.3% |
|---|---|---|
| Operating margin | 15.2% | 5.3% |
| Net margin | 4.7% | 3.5% |
| ROIC | 19.2% | 11.3% |
| ROE | 12.8% | 15.5% |
| Cash | $145M | $28.5B |
|---|---|---|
| Total debt | – | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | 1.6× | 6.2× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | 3.1% | 1.6% |
| Shareholder yield | 3.1% | 3.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($356B) is about 441.8 times Collegium Pharmaceutical ($806M), at today's prices.
Since November 17, 2016, COLL's price moved +54.6% and UNH's +160.3%. With dividends: COLL +54.6% (+4.5% a year), UNH +207.3% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Collegium Pharmaceutical and 2.31% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
At today's price, the P/E is 21.1 for COLL and 22.4 for UNH. The median of the last five years was 19.6 and 25.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 4.7% for Collegium Pharmaceutical and 3.5% for UnitedHealth, and the operating margin 15.2% and 5.3%. Revenue was $815M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.